Indivior PLC Ordinary Shares Total Assets
Indivior PLC Ordinary Shares total assets. Based on the latest financial reports, Indivior PLC Ordinary Shares (INDV) holds total assets worth $1.42 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Indivior PLC Ordinary Shares (INDV) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Indivior PLC Ordinary Shares (2016–2024)
Total assets of Indivior PLC Ordinary Shares from 2016 to 2024. This chart illustrates how Indivior PLC Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See Indivior PLC Ordinary Shares stock price for real-time trading data and today's change.
Indivior PLC Ordinary Shares - Asset Composition Analysis
Indivior PLC Ordinary Shares Total Assets Breakdown (December 2024)
Indivior PLC Ordinary Shares total assets breakdown as of December 2024. Indivior PLC Ordinary Shares's total assets of $1.42 Billion consist of 63.6% current assets and 36.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.2% |
| Accounts Receivable | $254.00 Million | 19.3% |
| Inventory | $178.00 Million | 13.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.00 Million | 0.4% |
| Goodwill | $2.00 Million | 0.2% |
Asset Composition Trend (2016–2024)
This chart illustrates how Indivior PLC Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore INDV current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Indivior PLC Ordinary Shares's current assets represent 63.6% of total assets in 2024, a decrease from 81.9% in 2016.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2024, down from 57.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 19.3% of total assets.
Indivior PLC Ordinary Shares Competitors by Total Assets
Key competitors of Indivior PLC Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Indivior PLC Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 0.83 | 1.80 |
| Quick Ratio | 0.79 | 0.65 | 1.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-43.00 Million | $-163.00 Million | $638.75 Million |
Indivior PLC Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Indivior PLC Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 145.25 |
| Latest Market Cap to Assets Ratio | 2.97 |
| Asset Growth Rate (YoY) | -32.5% |
| Total Assets | $1.32 Billion |
| Market Capitalization | $3.91 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Indivior PLC Ordinary Shares's assets at a significant premium (2.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Indivior PLC Ordinary Shares's assets decreased by 32.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Indivior PLC Ordinary Shares (2016–2024)
The table below shows the annual total assets of Indivior PLC Ordinary Shares from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.32 Billion | -32.50% |
| 2023-12-31 | $1.95 Billion | +9.86% |
| 2022-12-31 | $1.78 Billion | -2.73% |
| 2021-12-31 | $1.83 Billion | +19.43% |
| 2020-12-31 | $1.53 Billion | -7.32% |
| 2019-12-31 | $1.65 Billion | +6.79% |
| 2018-12-31 | $1.55 Billion | +7.13% |
| 2017-12-31 | $1.44 Billion | +19.44% |
| 2016-12-31 | $1.21 Billion | -- |
About Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more